Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $70 price target.
Gorilla Announces $25M Registered Direct Offering Of Convertible Preferred Stock
Gorilla Technology Group Inc. ("Gorilla") (NASDAQ:GRRR), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, today announced that it has entered into securities purchase agreements
